ATE445394T1 - Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienz - Google Patents
Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienzInfo
- Publication number
- ATE445394T1 ATE445394T1 AT04291738T AT04291738T ATE445394T1 AT E445394 T1 ATE445394 T1 AT E445394T1 AT 04291738 T AT04291738 T AT 04291738T AT 04291738 T AT04291738 T AT 04291738T AT E445394 T1 ATE445394 T1 AT E445394T1
- Authority
- AT
- Austria
- Prior art keywords
- citrulline
- aging
- radiation
- treatment
- production
- Prior art date
Links
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 title abstract 3
- 229960002173 citrulline Drugs 0.000 title abstract 2
- 230000000968 intestinal effect Effects 0.000 title abstract 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 title 1
- 230000032683 aging Effects 0.000 title 1
- 235000013477 citrulline Nutrition 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000005855 radiation Effects 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0308349A FR2857262B1 (fr) | 2003-07-08 | 2003-07-08 | Utilisation de la citrulline dans le cadre de l'insuffisance intestinale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE445394T1 true ATE445394T1 (de) | 2009-10-15 |
Family
ID=33443247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04291738T ATE445394T1 (de) | 2003-07-08 | 2004-07-08 | Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienz |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20050239891A1 (de) |
| EP (1) | EP1495755B8 (de) |
| AT (1) | ATE445394T1 (de) |
| DE (2) | DE04291738T1 (de) |
| ES (1) | ES2237355T1 (de) |
| FR (1) | FR2857262B1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065147A2 (en) * | 2005-12-01 | 2007-06-07 | Nps Pharmaceuticals, Inc. | A biomarker of improved intestinal function |
| US20090291877A1 (en) * | 2006-04-04 | 2009-11-26 | Nicolaas Emile Deutz | Treatments using citrulline |
| FR2907011B1 (fr) * | 2006-10-17 | 2010-05-14 | Univ Paris Descartes | Utilisation de la citrulline pour le traitement des etats de denutrition |
| JPWO2008105384A1 (ja) * | 2007-02-26 | 2010-06-03 | 協和発酵バイオ株式会社 | シトルリン含有錠剤 |
| FR2913885B1 (fr) * | 2007-03-22 | 2012-07-20 | Univ Paris Descartes | Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines |
| FR2970414B1 (fr) | 2011-01-14 | 2013-03-22 | Univ Paris Descartes | Action preventive de la citrulline sur le developpement spontane des tumeurs |
| IL246722A0 (en) * | 2016-07-11 | 2016-09-29 | Yeda Res & Dev | Combination therapy to increase endogenous nitric oxide (no) synthesis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189025A (en) * | 1988-12-09 | 1993-02-23 | Board Of Regenets, The University Of Texas System | Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions |
| FR2691359B1 (fr) * | 1992-05-20 | 1995-06-23 | Krempf Michel | Nouvelle application therapeutique du malate de 1-citrulline. |
| US5378722A (en) * | 1993-12-03 | 1995-01-03 | Clintec Nutrition Co. | Nutritional compositions for management of nitrogen metabolism |
| US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
| JP2004527501A (ja) * | 2001-03-05 | 2004-09-09 | ピー． アーネスト，スティーヴン | 経腸処方 |
-
2003
- 2003-07-08 FR FR0308349A patent/FR2857262B1/fr not_active Expired - Lifetime
-
2004
- 2004-07-08 DE DE04291738T patent/DE04291738T1/de active Pending
- 2004-07-08 EP EP04291738A patent/EP1495755B8/de not_active Expired - Lifetime
- 2004-07-08 AT AT04291738T patent/ATE445394T1/de not_active IP Right Cessation
- 2004-07-08 ES ES04291738T patent/ES2237355T1/es active Pending
- 2004-07-08 US US10/885,574 patent/US20050239891A1/en not_active Abandoned
- 2004-07-08 DE DE602004023564T patent/DE602004023564D1/de not_active Expired - Fee Related
-
2006
- 2006-06-30 US US11/477,861 patent/US20060247315A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1495755B1 (de) | 2009-10-14 |
| US20050239891A1 (en) | 2005-10-27 |
| FR2857262B1 (fr) | 2007-10-05 |
| DE04291738T1 (de) | 2005-08-18 |
| US20060247315A1 (en) | 2006-11-02 |
| ES2237355T1 (es) | 2005-08-01 |
| EP1495755B8 (de) | 2009-12-23 |
| DE602004023564D1 (de) | 2009-11-26 |
| EP1495755A1 (de) | 2005-01-12 |
| FR2857262A1 (fr) | 2005-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE449602T1 (de) | Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen | |
| ATE205389T1 (de) | Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
| ATE359087T1 (de) | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen | |
| CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
| DE602004015406D1 (de) | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen | |
| DE502004008819D1 (de) | Medikament zur wachstumsinhibierung von tumoren | |
| ATE445394T1 (de) | Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienz | |
| ATE549030T1 (de) | Verfahren zur behandlung und/oder prophylaxe von multipler sklerose, sowie verwendung von erythropoietin zur herstellung eines arzneimittels zur intermittierenden behandlung und/oder intermittierenden prophylaxe von multipler sklerose | |
| ATE289816T1 (de) | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen | |
| ATE311866T1 (de) | Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur | |
| DE69830586D1 (de) | Verwendung von gaba analoga wie gabapentin zur herstellung eines medikaments für die behandlung von entzündungserkrankungen | |
| EP4203986A4 (de) | Verwendung von mangostenfruchtschalenextrakt zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| DE60027127D1 (de) | Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen | |
| RU2423118C1 (ru) | Способ лечения трофических язв | |
| ATE535237T1 (de) | Verwendung von fts zur behandlung von malignen erkrankungen | |
| ATE388719T1 (de) | Verwendung von feigenkaktus (opuntia) zur herstellung eines medikaments zur behandlung von depressionen | |
| ATE247956T1 (de) | Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien | |
| EP4609863A4 (de) | Verwendung von ly292470 zur herstellung eines arzneimittels zur vorbeugung oder behandlung von nierenerkrankungen | |
| ATE234613T1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| DE60326262D1 (de) | Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden | |
| EP4324464A4 (de) | Verwendung von adenin zur herstellung eines arzneimittels zur behandlung von diabetischen ulcera | |
| ATE418977T1 (de) | Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |